Page last updated: 2024-12-07

n-(9h-(2,7-dimethylfluoren-9-ylmethoxy)carbonyl)leucine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-(9H-(2,7-dimethylfluoren-9-ylmethoxy)carbonyl)leucine: RN given refers to the (L-Leu)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID119365
CHEMBL ID42385
SCHEMBL ID8066678
MeSH IDM0193608

Synonyms (15)

Synonym
npc 15669
npc-15669
n-(((2,7-dimethyl-9h-fluoren-9-yl)methoxy)carbonyl)-l-leucine
n-(9h-(2,7-dimethylfluoren-9-ylmethoxy)carbonyl)leucine
l-leucine, n-(((2,7-dimethyl-9h-fluoren-9-yl)methoxy)carbonyl)-
CHEMBL42385
(2s)-2-[(2,7-dimethyl-9h-fluoren-9-yl)methoxycarbonylamino]-4-methylpentanoic acid
unii-k6jbn2t3z4
k6jbn2t3z4 ,
132684-62-9
SCHEMBL8066678
(2s)-2-({[(2,7-dimethyl-9h-fluoren-9-yl)methoxy]carbonyl}amino)-4-methylpentanoic acid
EN300-6493720
n-{[(2,7-dimethyl-9h-fluoren-9-yl)methoxy](hydroxy)methylidene}leucine
DTXSID70927775

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Here we report the in vivo effects of a dose-response study using 2 new members of another class of Mac-1 directed agents designated nactins."( The role of CD11b/CD18 mediated neutrophil adhesion in complement deficient xenograft recipients.
Baldwin, WM; Davis, EA; Jakobs, FM; Liu, DY; Qian, Z; Sanfilippo, F, 1997
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID91169In vitro ability to inhibit the adhesion of neutrophil activated by tumor necrosis factor (alpha-TNF) to serum-coated plastic wells.1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Fluorenylalkanoic and benzoic acids as novel inhibitors of cell adhesion processes in leukocytes.
AID84820In vitro ability to activate polymorpho nuclear granulocytes using IFN gamma-(HUVEC) assay was determined1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Fluorenylalkanoic and benzoic acids as novel inhibitors of cell adhesion processes in leukocytes.
AID160506LD50 value for polymorphonuclear granulocytes was determined1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Fluorenylalkanoic and benzoic acids as novel inhibitors of cell adhesion processes in leukocytes.
AID67830LD50 value for endothelial cells was determined1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Fluorenylalkanoic and benzoic acids as novel inhibitors of cell adhesion processes in leukocytes.
AID91168In vitro ability to inhibit the adhesion of neutrophil activated by platelet activating factor (PAF) to serum-coated plastic wells was determined1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Fluorenylalkanoic and benzoic acids as novel inhibitors of cell adhesion processes in leukocytes.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's32 (96.97)18.2507
2000's1 (3.03)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.84 (24.57)
Research Supply Index3.61 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.78%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other35 (97.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]